Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Immutep Ltd ( (AU:IMM) ) has shared an announcement.
Immutep Limited has received positive feedback from the FDA regarding the clinical development of its MHC Class II agonist, eftilagimod alfa, for treating head and neck squamous cell carcinoma patients with low PD-L1 expression. The FDA’s support highlights the potential of eftilagimod alfa in combination with KEYTRUDA to address unmet medical needs in this patient segment, paving the way for further clinical trials and potential accelerated approval, which could significantly impact the company’s operations and industry positioning.
The most recent analyst rating on (AU:IMM) stock is a Buy with a A$2.00 price target. To see the full list of analyst forecasts on Immutep Ltd stock, see the AU:IMM Stock Forecast page.
More about Immutep Ltd
Immutep Limited is a late-stage biotechnology company that develops novel immunotherapies for cancer and autoimmune diseases. The company is a pioneer in the development of therapeutics related to Lymphocyte Activation Gene-3 (LAG-3), leveraging its expertise to create innovative treatments and maximize shareholder value.
Average Trading Volume: 3,399,110
Technical Sentiment Signal: Sell
Current Market Cap: A$381.6M
Find detailed analytics on IMM stock on TipRanks’ Stock Analysis page.